FOXO Tech unit Vector BioSource to buy 4 blood centers from Grifols for $3.5M plus earn-out

FOXO TECHNOLOGIES INC.

Vector BioSource, a FOXO subsidiary, agreed to buy four blood collection centers from Grifols Bio Supplies for $3.5M cash at closing.
Earn-out of up to $1M payable if acquired business generates EBITDA of $1.5M or more in any calendar year 2026-2028.
Closing conditioned on Vector obtaining new FDA license, CLIA certification, and waste-management permit independent of seller.
Closing expected in Q3 or Q4 2026; long stop date is nine months from July 22, 2026.
Acquired assets include serum inventory and existing cell units at the four collection centers.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.